Skip to main content
. 2016 Aug 18;2016:bcr2016215801. doi: 10.1136/bcr-2016-215801

FigureĀ 1.

FigureĀ 1

VEGF receptor 2 (based on Lankhorst et al16). VEGF-A binds to the thyrosine kinase receptor VEGF receptor 2 and by activating this pathway promotes angiogenesis and lymphangiogenesis. Ramucirumab inhibits this pathway by binding to the VEGF receptor 2. VEGF, vascular endothelial growth factor.